Lucia Indrei

Ms. Lucia Indrei


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 October 2024 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
VSVictorita Sorodoc
Victorita Sorodoc
LILucia Indrei
Lucia Indrei
Catinca DobroghiiCatinca Dobroghii
Catinca Dobroghii
AAAndreea Asaftei
Andreea Asaftei
Alexandr Ceasovschih, Assist. Prof., PhDAlexandr Ceasovschih, Assist. Prof., PhD
Alexandr Ceasovschih, Assist. Prof., PhD
LȘLaurențiu Șorodoc
Laurențiu Șorodoc
Amiodarone, a bi-iodinated benzofuran derivative, is among the most commonly used antiarrhythmic drugs due to its high level of effectiveness. Though initially categorized as a class III agent, amiodarone exhibits antiarrhythmic properties across all four classes of antiarrhythmic drugs. Amiodarone is highly effective in maintaining sinus rhythm in patients with paroxysmal atrial fibrillation while also playing a crucial role in preventing a range of ventricular arrhythmias. Amiodarone has a complex pharmacokinetic profile, characterized by a large volume of distribution and a long half-life, which can range from several weeks to months, resulting in prolonged effects even after discontinuation. Side effects may include thyroid dysfunction, pulmonary fibrosis, and hepatic injury, necessitating regular follow-ups. Additionally, amiodarone interacts with several drugs, including anticoagulants, which must be managed to prevent adverse effects. Therefore, a deep understanding of both oral and intravenous formulations, as well as proper dosage adjustments, is essential. The aim of this paper is to provide a comprehensive and updated review on amiodarone’s indications, contraindications, recommended dosages, drug interactions, side effects, and monitoring protocols.